DUGi

Photodynamic therapy as an alternative to progestogens in endometrial cancer grade 1A G1: multicenter clinical analysis

http://dugi.udg.edu/item/http:@@@@hdl.handle.net@@10256@@22969

Endometrial neoplasia is the most prevalent gynecological cancer in developed countries. Although diagnoses during the fertile age is less significant, the standard treatment is surgery. In case of reproductive desire and stage 1A G1/G2 endometrial carcinoma, an alternative treatment (oral progestogens) can be administrated. This treatment has a low response rate (57-75%), presents recurrences (11-50%) and various systemic side effects. On the other hand, photodynamic therapy has been used to detect and combat malignant lesions on the cervix, endometrium, vulva, vagina, breast and ovarian, because it reduces the adverse effects of conventional treatments. To compare treatment with oral progestogens and photodynamic therapy in stage 1A G1/G2 endometrial carcinoma without myometrial involvement in patients without associated genetic factors: remission rate, time to cure, recurrence rate, adverse effects, quality of life of patients and reproductive desire. This experiment scientific study is a multicenter, national, parallel-group, prospective, randomized, open label but blinded for the end-point evaluators (PROBE) clinical trial. This study includes all those patients under 40 years of age with a gestational desire, without associated genetic factors and who have been diagnosed with stage 1A G1/G2 endometrial cancer, without myometrial invasion or adnexal extension, in public or private hospitals in Spain. A non-probabilistic consecutive sampling method will be followed in the Gynecology and Obstetrics Unit of each participating hospital. Once a sample of 430 patients has been recruited, they are randomly divided into two groups

3